Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

11–14 More serious infections, opportunistic infections and herpes zoster events were reported with upadacitinib 30 mg compared with upadacitinib 15 mg and placebo; however, percentages of malignancy ...